BioPharma Clinical Trials

Akeso’s Ivonescimab Shows Significant Overall Survival Benefit Over Pembrolizumab in Phase III NSCLC Trial

Akeso, Inc. announced that a pre-specified interim analysis of overall survival (OS) in the HARMONi-2 (AK112-303) trial, as assessed by the Independent Dat...

 September 04, 2026 | News

Norroy Bioscience Secures China Clearance for Phase III Trial of PSMA-Targeted Radiopharmaceutical

NORROY BIOSCIENCE (NORROY), a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals, announced that it has received regu...

 September 04, 2026 | News

Everest Medicines Secures China Approval for CARDAMYST to Treat Acute PSVT Episodes

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, a...

 September 04, 2026 | News

Cartherics Explores Tissue Factor-Targeting CAR-NK Therapies for Cancer and Endometriosis

Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing off-the-shelf immu...

 September 03, 2026 | News

Singapore Becomes First ASEAN Market to Subsidise Vutrisiran for ATTR Amyloidosis

"From September 2026 – eligible patients receiving vutrisiran will receive government subsidies of up to 75%[1],[2]" "HELIOS-A and B provide strong ...

 September 02, 2026 | News

Ascletis Doses First Patient in Global Phase III Programme for Oral GLP-1 Obesity Drug ASC30

- Expected to enroll approximately 4,600 participants with obesity or overweight across two pivotal trials (AURORA-1 and AURORA-2) in the U.S., Europe, and...

 September 01, 2026 | News

HiRO and Differentia Join Forces to Advance AI-Powered Clinical Trial Simulation and Digital Twins

Memorandum of Understanding establishes a framework for joint development of clinical trial simulation capabilities The partnership unites global clinic...

 August 31, 2026 | News

Sanyou Bio Launches AI-Powered Clicklinks to Accelerate Global Drug Discovery and Preclinical Development

Sanyou Biopharmaceuticals Co., Ltd. (hereinafter referred to as "Sanyou Bio"),  announced the official launch of Clicklinks, an AI-STAL and SAI-DA pow...

 August 31, 2026 | News

HaemaLogiX Doses First Patient with KMCAR T-Cell Therapy in Phase 1 Multiple Myeloma Trial

First patient safely dosed in Phase 1 KOALA trial evaluating KMCAR™ T-cell therapy in patients with relapsed/refractory kappa-restricted multiple m...

 August 27, 2026 | News

WuXi XDC H1 2026 Revenue Jumps 37% to RMB 3.7 Bn on Strong Bioconjugate Demand

Group total revenue increased to RMB 3,701.4 million, representing 37.0% period-over-period growth on an AER[1] basis (41.5% growth on a CER[2]...

 August 26, 2026 | Company results

Antengene’s ATG-201 Wins Australian Clearance for Phase I Autoimmune Disease Trial

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, develop...

 August 26, 2026 | News

Pulnovo Medical Enrols First Patients in PULSE-LHD Trial for Pulmonary Hypertension

Pulnovo Medical, a globally recognized pioneer in medical devices for pulmonary hypertension (PH) and heart failure (HF), announced the enrollment of the f...

 August 24, 2026 | News

Akeso Secures China Clinical Trial Clearance for B7-H3 ADC AK157D1

Akeso, Inc. announced that its investigational next-generation B7-H3-targeting antibody-drug conjugate (ADC), AK157D1, has received clinical trial clearanc...

 August 24, 2026 | News

Leads Biolabs’ Opamtistomig NDA Accepted in China for Advanced EP-NEC

Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced the Center for Drug Evaluation (CDE) of China'...

 August 24, 2026 | News


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close